Key result
Ticagrelor cuts MACE ~16% vs clopidogrel in ACS, but increases bleeding in high-risk cohorts.
Why the study?
Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist is the cornerstone of ACS pharmacotherapy. This review was conducted to critically compare ticagrelor against clopidogrel across pharmacological profiles, randomized controlled trials, observational registries, pharmacogenomic variations, special populations, and clinical practice guidelines.
Does ticagrelor improve ischemic outcomes and maintain acceptable bleeding safety compared to clopidogrel in patients with acute coronary syndrome across diverse clinical and demographic subpopulations?
Systematic Review
Does ticagrelor improve ischemic outcomes and maintain acceptable bleeding safety compared to clopidogrel in patients with acute coronary syndrome across diverse clinical and demographic subpopulations?
Answers are grounded in this paper and cite their sources.
While ticagrelor is superior to clopidogrel for reducing ischemic events in general Western ACS populations, clopidogrel provides a superior net clinical benefit with lower bleeding risk in East Asian and elderly (≥70–75 years) patients, supporting individualized P2Y12 inhibitor selection.
Background & Aim: Dual antiplatelet therapy (DAPT) combining aspirin with a P2Y12 receptor antagonist is the cornerstone of pharmacotherapy in acute coronary syndrome (ACS), including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation acute coronary syndrome (NSTE-ACS). This structured review critically compares the direct-acting, reversible P2Y12 inhibitor ticagrelor against the second-generation thienopyridine prodrug clopidogrel across pharmacological profiles, landmark randomized controlled trials (RCTs), observational registries, pharmacogenomic variations, special populations, and clinical practice guidelines. Methods: A multi-database systematic literature synthesis was conducted using PubMed/MEDLINE, Embase, Cochrane Library, and Web of Science (2010–2026). Evidence was synthesized across STEMI, NSTEMI, percutaneous coronary intervention (PCI), medically managed ACS, and fibrinolytic therapy without quantitative statistical pooling. Results: Landmark global trial evidence (e.g., PLATO) demonstrates that ticagrelor significantly reduces major adverse cardiovascular events (MACE, HR=0.84,95% CI 0.77–0.92) and cardiovascular death compared to clopidogrel, particularly in invasively managed populations and high-risk patients. However, real-world observational registries and East Asian population cohorts (e.g., PHILO, TICAKOREA, COSTIC) demonstrate an 'East Asian Paradox' where standard-dose ticagrelor confers no significant ischemic benefit over clopidogrel but markedly elevates bleeding risk (BARC 2–5). Furthermore, in elderly ACS patients (‡70–75 years; POPular AGE trial) and low-risk elective PCI settings (ALPHEUS trial), clopidogrel exhibits non-inferior net clinical benefit with significantly superior bleeding safety. Conclusion: While international guidelines maintain Class I recommendations for ticagrelor over clopidogrel in general ACS, therapeutic selection must be individualized according to validated risk scores (PRECISE-DAPT, ARC-HBR), age, geographic/ethnicity factors, oral anticoagulation requirements, and patient adherence
No takes yet. Share an insight, caveat, or question.
OO et al. (2026) conducted a systematic review in Acute coronary syndrome (STEMI, NSTEMI, and unstable angina). Ticagrelor vs. Clopidogrel (300 to 600 mg loading dose, followed by 75 mg once daily) on a background of aspirin was evaluated on Major adverse cardiovascular events (composite of cardiovascular death, myocardial infarction, or stroke in the landmark PLATO trial) (HR 0.84, 95% CI 0.77–0.92, p=<0.001). Ticagrelor reduced major adverse cardiovascular events compared to clopidogrel in global ACS trials (PLATO HR 0.84, 95% CI 0.77–0.92), but increased bleeding in East Asian and elderly cohorts.
Synapse has enriched 10 related papers. Consider them for comparative context: